Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling
Open accessThe DOI matches its Crossref record; 131 of the 133 references it cites were found in a registry or an index.
Abstract
Oxidative cellular damage caused by free radicals is known to contribute to the pathogenesis of various diseases such as cancer, diabetes, and neurodegenerative diseases, as well as to aging. The transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) and Kelch-like ECH-associated protein1 (Keap1) signaling pathways play an important role in preventing stresses including oxidative and inflammatory stresses. Nrf2 is a master regulator of cellular stress responses, induces the expression of antioxidant and detoxification enzymes, and protects against oxidative stress-induced cell damage. Glucagon-like peptide-1 (GLP-1) is an incretin hormone, which was originally found to increase insulin synthesis and secretion. It is now widely accepted that GLP-1 has multiple functions beyond glucose control in various tissues and organs including brain, kidney, and heart. GLP-1 and GLP-1 receptor agonists are known to be effective in many chronic diseases, including diabetes, via antioxidative mechanisms. In this review, we summarize the current knowledge regarding the role of GLP-1 in the protection against oxidative damage and the activation of the Nrf2 signaling pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“dysfunction of endothelial cells, induced by hyperglycemia and driven by this systemic proinflammatory state, trigger cardiomyocyte dysfunction in HFpEF.”
From The cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF (2023) · cites this paper as [66]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The Nrf2 signaling pathway, a master regulator of cellular antioxidant defense mechanisms, is upregulated by GLP-1 receptor activation, according to preclinical research (49).”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Improvements in HF-related symptoms and physical function have been broadly recognized as key goals of care in patients with HFpEF by clinicians, professional societies and regulators. 45”
From Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials (2024) · cites this paper as [45]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Free radicals, metals and antioxidants in oxidative stress-induced cancer
Valko, M., Rhodes, C. J., Moncol, J., Izakovic, M., & Mazur, M. (2006) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2005.12.009 · Cited by 6,680
Oxidative stress, inflammation, and cancer: How are they linked?
Reuter, S., Gupta, S. C., Chaturvedi, M. M., & Aggarwal, B. B. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.09.006 · Cited by 5,441
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 2×
“In addition to its actions on the pancreas, GLP-1 reduces glucose production in the liver and increases glucose uptake in adipose tissue and muscle [64,78,79].”
BackgroundCell Survival Responses to Environmental Stresses Via the Keap1-Nrf2-ARE Pathway
Kensler, T. W., Wakabayashi, N., & Biswal, S. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141046 · Cited by 3,630 · cited 2×
“Under basic conditions, Nrf2 is bound to the endogenous inhibitor Kelch-like ECH-associated protein1 (Keap1), which is anchored to actin in the cytoskeleton in the cytosol, and suppressed by Keap1-dependent ubiquitination-proteasomal degradation [8].”
BackgroundThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 1×
“GLP-1 has many additional effects; it delays gastric emptying, inhibits food intake, improves insulin sensitivity, inhibits glucagon secretion, and stimulates insulin biosynthesis [18,53].”
BackgroundThe Nrf2 regulatory network provides an interface between redox and intermediary metabolism
Hayes, J. D., & Dinkova-Kostova, A. T. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.02.002 · Cited by 2,141 · cited 2×
“Nrf2–ARE binding regulates the expression of genes involved in cellular antioxidant and anti-inflammatory responses such as superoxide dismutase, catalase, glutathione peroxidases, thioredoxin, thioredoxin reductase, sulfiredoxin, NADPH:quinone oxidoreductase-1, heme oxygenase-1, glutathione reductase, glutaredoxin, g…”
BackgroundAntioxidants Maintain Cellular Redox Homeostasis by Elimination of Reactive Oxygen Species
He, L., He, T., Farrar, S., Ji, L., Liu, T., & Ma, X. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000485089 · Cited by 2,127
Cellular mechanisms and physiological consequences of redox-dependent signalling
Holmström, K. M., & Finkel, T. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3801 · Cited by 2,093
Oxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053
Strategies of antioxidant defense
SIES, H. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb18025.x · Cited by 1,976
Cited by
Burgos-Morón, E., Abad-Jiménez, Z., Martínez de Marañón, A., Iannantuoni, F., Escribano-López, I., López-Domènech, S., Salom, C., Jover, A., Mora, V., Roldan, I., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091385 · Cited by 581
Butler, J., Shah, S. J., Petrie, M. C., Borlaug, B. A., Abildstrøm, S. Z., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Verma, S., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00469-0 · Cited by 386
Flavonoids: A treasure house of prospective pharmacological potentials
Hasnat, H., Shompa, S. A., Islam, M. M., Alam, S., Richi, F. T., Emon, N. U., Ashrafi, S., Ahmed, N. U., Chowdhury, M. N. R., Fatema, N., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27533 · Cited by 263
“However, flavonoids block MAPK activation [129,210] as well as the Nrf-2 signaling pathway [116,212] (Figs.”
BackgroundZhao, T., Wu, W., Sui, L., Huang, Q., Nan, Y., Liu, J., & Ai, K. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.06.006 · Cited by 267
“Ginsenoside Rg3 (Rg3), the active constituent in ginseng, has been shown to prevent myocardial ischemia reperfusion injury via enhancing the SOD activity [24].”
BackgroundInfluentialRekatsina, M., Paladini, A., Piroli, A., Zis, P., Pergolizzi, J. V., & Varrassi, G. (2020) · Advances in Therapy · doi:10.1007/s12325-019-01148-5 · Cited by 252
Salameh, T. S., Rhea, E. M., Talbot, K., & Banks, W. A. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114187 · Cited by 188
Recent Developments of Biomaterials for Additive Manufacturing of Bone Scaffolds
Chen, Y., Li, W., Zhang, C., Wu, Z., & Liu, J. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000724 · Cited by 162
Kanwal, F., Kramer, J. R., Li, L., Yang, Y.-X., Cao, Y., Yu, X., Samuel, R., Ali, B., Desiderio, R., Cholankeril, G., et al. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.4661 · Cited by 156
Andreadi, A., Bellia, A., Daniele, N. D., Meloni, M., Lauro, R., Della‐Morte, D., & Lauro, D. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.11.010 · Cited by 144
Role of Edaravone as a Treatment Option for Patients with Amyotrophic Lateral Sclerosis
Cho, H., & Shukla, S. (2020) · Pharmaceuticals · doi:10.3390/ph14010029 · Cited by 124
Wang, L., Liu, Y., Zhang, X., Ye, Y., Xiong, X., Zhang, S., Gu, L., Jian, Z., & Wang, H. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.864426 · Cited by 121
Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis
Mann, J. F. E., Buse, J. B., Idorn, T., Leiter, L. A., Pratley, R. E., Rasmussen, S., Vilsbøll, T., Wolthers, B., & Perkovic, V. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14443 · Cited by 120
GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease
Kalinderi, K., Papaliagkas, V. T., & Fidani, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073812 · Cited by 130
“…(Ser112), and reduce the pro-apoptotic protein Bax and inhibit caspase-3 activity GLP-1 has been suggested to decrease oxidative stress via receptor-mediated stimulation of the cyclic AMP, PI3K and protein kinase C pathways and activation of nuclear factor erythroid 2-related factor 2 (Nrf-2) [84].”
BackgroundGaur, P., Prasad, S., Kumar, B., Sharma, S. K., & Vats, P. (2020) · International Journal of Biometeorology · doi:10.1007/s00484-020-02037-1 · Cited by 115
“During stress condition, Nrf2 is released from KEAP1 (Kelch-like erythroid cell–derived protein with CNC homology [ECH]–associated protein 1) (Oh and Jun 2017; Huang et al. 2002).”
BackgroundMolecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity
Yaribeygi, H., Sathyapalan, T., & Sahebkar, A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116776 · Cited by 102
Min, J. S., Jo, S. J., Lee, S., Kim, D. Y., Kim, D. H., Lee, C. B., & Bae, S. K. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s506957 · Cited by 132
Yaribeygi, H., Rashidy-Pour, A., Atkin, S. L., Jamialahmadi, T., & Sahebkar, A. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118645 · Cited by 96
Yaribeygi, H., Butler, A. E., Barreto, G. E., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27278 · Cited by 104
“Oh and Jun (2017) reported that GLP‐1 agonists have the potent antioxidative ability by upregulating Nrf2 (nuclear factor erythroid 2‐ related Factor 2) and Keap1 (Kelch‐like ECH‐associated protein1).”
BackgroundLiraglutide attenuates hepatic iron levels and ferroptosis in db/db mice
Song, J., An, J., Chen, Q., Yang, X., Jia, C., Xu, S., Zhao, Y., & Ji, E. (2022) · Bioengineered · doi:10.1080/21655979.2022.2051858 · Cited by 108
“The liraglutide could improve system Xc − and Nrf2 /HO-1 pathway to against to ferroptosis in liver of db/db mice.”
BackgroundInfluentialKarakasis, P., Theofilis, P., Vlachakis, P. K., Korantzopoulos, P. G., Patoulias, D., Antoniadis, A. P., & Fragakis, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010209 · Cited by 112
Therapeutic Potential of Ursolic Acid in Cancer and Diabetic Neuropathy Diseases
Alam, M., Ali, S., Ahmed, S., Elasbali, A. M., Adnan, M., Islam, A., Hassan, M. I., & Yadav, D. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212162 · Cited by 93
Roy, B. (2025) · Medical Sciences · doi:10.3390/medsci13030087 · Cited by 131
Prattichizzo, F., de Candia, P., & Ceriello, A. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154799 · Cited by 82
Effects of lycopene on metabolism of glycolipid in type 2 diabetic rats
Yin, Y., Zheng, Z., & Jiang, Z. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.07.100 · Cited by 79
The cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF
Withaar, C., Meems, L. M. G., Nollet, E. E., Schouten, E. M., Schroeder, M. A., Knudsen, L. B., Niss, K., Madsen, C. T., Hoegl, A., Mazzoni, G., et al. (2023) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2023.05.012 · Cited by 74
“63 64-66 Several animal studies and studies with patients with T2DM have already shown that GLP-1RAs have anti-in fl ammatory and antioxidant properties, and this may re fl ect a pathway by which semaglutide exerts (a part of) its effects.”
BackgroundThe Role of Oxidative Stress Enhanced by Adiposity in Cardiometabolic Diseases
Świątkiewicz, I., Wróblewski, M., Nuszkiewicz, J., Sutkowy, P., Wróblewska, J., & Woźniak, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076382 · Cited by 88
Sadek, M. A., Kandil, E. A., Sayed, N. S. E., Sayed, H. M., & Rabie, M. A. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109647 · Cited by 71
Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes
Yaribeygi, H., Maleki, M., Sathyapalan, T., Jamialahmadi, T., & Sahebkar, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2019.117152 · Cited by 63
Thomas, M. C., Coughlan, M. T., & Cooper, M. E. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.004 · Cited by 56
Targeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists
Ghosh, P., Fontanella, R. A., Scisciola, L., Pesapane, A., Taktaz, F., Franzese, M., Puocci, A., Ceriello, A., Prattichizzo, F., Rizzo, M. R., et al. (2023) · Theranostics · doi:10.7150/thno.86831 · Cited by 73
“GLP-1RA also interfere with activating a master regulator of cellular oxidative stress erythroid nuclear factor 2-related nuclear factor 2 (Nrf2) [8].”
BackgroundInfluentialRen, Y., Chen, Y., Zheng, W., Kong, W., Liao, Y., Zhang, J., Wang, M., & Zeng, T. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16366 · Cited by 59
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Obstructive Pulmonary Disease
Wang, W., Mei, A., Qian, H., Li, D., Xu, H., Chen, J., Yang, H., Min, X., Li, C., Cheng, L., et al. (2023) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s393323 · Cited by 53
“mechanism by which GLP-1 reduces oxidative stress can be mediated through the cAMP, PI3K and PKC pathways.(21)”
BackgroundTherapeutic application of GLP-1 and GIP receptor agonists in Parkinson’s disease
Yang, X., Feng, P., Ji, R., Ren, Y., Wei, W., & Hölscher, C. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2079492 · Cited by 50
“2-related factor 2 (Nrf-2, a transcription factor involved in regulating oxidative stress), which consequently enhanced the antioxidant activity [170].”
BackgroundRaissi-Dehkordi, N., Raissi-Dehkordi, N., Ebrahimibagha, H., Tayebi, T., Moeinabadi‐Bidgoli, K., Hassani, M., & Niknejad, H. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1527736 · Cited by 60
“However, when tissues are subjected to ROS generated following exposure to atmospheric pressure plasma, excessive levels of oxidative stress inactivate KEAP1, allowing the accumulation and translocation of NRF2 to the nucleus (35, 36).”
GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?
Menghini, R., Casagrande, V., Rizza, S., & Federici, M. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02124-w · Cited by 47
“GLP-1R acts in many pathways involved in the regulation of endothelial function [15]; 2.”
BackgroundBala, C. G., Rusu, A., Ciobanu, D. M., Bucșa, C., & Román, G. (2021) · Antioxidants · doi:10.3390/antiox10040610 · Cited by 53
“Previous research has shown that therapy with GLP-1 receptor agonists is associated with reductions in markers of oxidative stress [40].”
Atrial Cardiomyopathy in Atrial Fibrillation: Mechanistic Pathways and Emerging Treatment Concepts
Karakasis, P., Theofilis, P., Vlachakis, P. K., Ktenopoulos, N., Patoulias, D., Antoniadis, A. P., & Fragakis, N. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14093250 · Cited by 57
Lee, C.-C., Chen, W.-T., Chen, S., & Lee, T. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114674 · Cited by 46
Bılgın, E., Venerito, V., & Bogdanos, D. P. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103864 · Cited by 57
Yassine, H. N., Solomon, V., Thakral, A., Sheikh‐Bahaei, N., Chui, H. C., Braskie, M. N., Schneider, L. S., & Talbot, K. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12474 · Cited by 43
Wang, M., Liu, Y., Liang, Y. T., Naruse, K., & Takahashi, K. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.649785 · Cited by 64
“For example, GLP-1 exerts antioxidant effects via cyclic adenosine monophosphate (cAMP), phosphoinositide 3-kinase (PI3K), and protein kinase C-delta (PKCδ) pathways in diabetes (120).”
BackgroundManavi, M. A. (2022) · Neuropeptides · doi:10.1016/j.npep.2022.102250 · Cited by 40
Neuroprotective effects of GLP-1 class drugs in Parkinson’s disease
Lv, D., Feng, P., Guan, X., Liu, Z., Li, D., Xue, C., Bai, B., & Hölscher, C. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1462240 · Cited by 49
Padmavathi, G., & Ramkumar, K. M. (2020) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2020.108725 · Cited by 40
Urkon, M., Ferencz, E., Szász, J. A., Szabó, M. I. M., Orbán-Kis, K., Szatmári, S., & Nagy, E. E. (2025) · Pharmaceuticals · doi:10.3390/ph18050614 · Cited by 45
“GLP-1 signaling may also interfere with oxidative stress at the level of antioxidant enzyme gene expression, as it regulates the nuclear erythroid-2-like factor-2/antioxidant response element (Nrf2/ARE) pathway via PI3K and Akt activation [155].”
The Gut‐Brain Axis in Parkinson disease: Emerging Concepts and Therapeutic Implications
Menozzi, E., Schapira, A. H. V., & Borghammer, P. (2025) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.70029 · Cited by 46
Zhou, W., Shao, W., Zhang, Y., Liu, D., Liu, M., & Jin, T. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00292.2020 · Cited by 36
“They can protect pancreatic b-cells from high glucose or oxidative stress-induced cell apoptosis, and this feature can be shared by other cell lineages (27, 44).”
BackgroundRavarotto, V., Bertoldi, G., Innico, G., Gobbi, L., & Calò, L. A. (2021) · Antioxidants · doi:10.3390/antiox10071041 · Cited by 38
“In addition, the glucagon-like peptide 1 (GLP-1), an hormone that stimulates insulin secretion and downregulates glucagon secretion [78] has been shown to decrease oxidative stress and to promote antioxidant effects through the activation of nuclear erythroid-2 like factor-2 (Nrf2) and to improve mitochondrial functio…”
BackgroundAntidiabetic drugs and oxidized low-density lipoprotein: A review of anti-atherosclerotic mechanisms
Ahmadi, A., Panahi, Y., Johnston, T. P., & Sahebkar, A. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105819 · Cited by 39
Recent Pharmacological Options in Type 2 Diabetes and Synergic Mechanism in Cardiovascular Disease
Andreadi, A., Muscoli, S., Tajmir, R., Meloni, M., Muscoli, C., Ilari, S., Mollace, V., Della‐Morte, D., Bellia, A., Daniele, N. D., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021646 · Cited by 39
Semaglutide Ameliorates Diabetic Neuropathic Pain by Inhibiting Neuroinflammation in the Spinal Cord
Lee, S.-O., Kuthati, Y., Huang, W.-H., & Wong, C. (2024) · Cells · doi:10.3390/cells13221857 · Cited by 46
Zhang, Y., Qian, P., Zhou, H., Shen, R., Hu, B., Shen, Y., Zhang, X., Shen, X., Xu, G., & Jin, L. (2018) · Kidney & Blood Pressure Research · doi:10.1159/000492409 · Cited by 34
Wang, Z., Huang, Y., Lu, W., Liu, J., Li, X., Zhu, S., Liu, H., & Song, Y. (2022) · Medical Oncology · doi:10.1007/s12032-022-01736-6 · Cited by 40
Carboxymethylated pachyman induces ferroptosis in ovarian cancer by suppressing NRF1/HO‑1 signaling
Jing, T., Guo, Y., & Wei, Y. (2022) · Oncology Letters · doi:10.3892/ol.2022.13281 · Cited by 33
“Oxidative damage induced via free radicals promotes the pathogenesis of multiple diseases, including cancer (21).”
BackgroundChen, L., Chen, X., Ruan, B., Yang, H., & Yu, Y. (2024) · Peptides · doi:10.1016/j.peptides.2024.171245 · Cited by 31
Abiola, J. O., Oluyemi, A. A., Idowu, O. T., Oyinloye, O. M., Ubah, C. S., Owolabi, O. V., Somade, O. T., Onikanni, S. A., Ajiboye, B. O., Osunsanmi, F. O., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17060736 · Cited by 40
“Extensive research has focused on elucidating how GLP-1 receptor agonists (GLP-1RAs) counteract the detrimental effects of ER stress [141], oxidative stress [142], and autophagy [143].”
BackgroundVascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients
Correale, M., Lamacchia, O., Ciccarelli, M., Dattilo, G., Tricarico, L., & Brunetti, N. D. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10157-y · Cited by 33
Rroji, M., Spahia, N., Figurek, A., & Spasovski, G. B. (2025) · Biomedicines · doi:10.3390/biomedicines13030728 · Cited by 34
“These pathways subsequently activate the nuclear factor erythroid 2–related factor 2 (Nrf2) pathway, enhancing the cell’s antioxidant defenses [117].”
Hu, Y. H., Luo, Y., & Zheng, Y. (2022) · Antioxidants · doi:10.3390/antiox11091747 · Cited by 33
Ma, T., Shi, Y., & Wang, Y. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10312 · Cited by 27
“nrf2 is a master regulator of cellular stress responses, inducing the expression of antioxidant and detoxification enzymes, and preventing oxidative stress‐induced cell injury (29).”
BackgroundKim, H., Joo, Y., Kook, Y.-M., Tran, N. L., Kim, S., Lee, K., & Oh, S. J. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c20394 · Cited by 26
Neurodegenerative Diseases: New Hopes and Perspectives
Bhat, M. A., & Dhaneshwar, S. S. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230907093451 · Cited by 31
Kuthati, Y., Davuluri, V. N. G., & Wong, C. (2025) · Biomolecules · doi:10.3390/biom15050622 · Cited by 32
“GLP-1-RA-based therapies, through their antioxidant properties, may help alleviate oxidative stress, reduce neuronal damage, and, consequently, decrease pain [86].”
Li, D., Hu, Z., Qian, H., Guo, Y., Chong, Y., Xu, J., & Qin, L. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c06813 · Cited by 26
D’Marco, L., Morillo, V., Górriz, J. L., Suarez, M., Nava, M., Ortega, Á., Parra, H., Villasmil, N., Rojas, J., & Bermúdez, V. (2021) · Journal of Diabetes Research · doi:10.1155/2021/9032378 · Cited by 33
“In the kidney, GLP-1RA have also demonstrated an antioxidant and anti-inflammatory role [109].”
BackgroundTabaa, M. M. E., Tabaa, M. M. E., Anis, A., Elgharabawy, R. M., & El-Borai, N. B. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108995 · Cited by 25
Atabi, F., Moassesfar, M., Nakhaie, T., Bagherian, M., Hosseinpour, N., & Hashemi, M. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01930-2 · Cited by 46
“Glucagon-Like Peptide-1 (GLP-1) agonists, like liraglutide, reduce oxidative stress by activating NRF2, a transcription factor regulating antioxidant response elements (AREs) [141].”
Do, M. H., Lee, J. H., Ahn, J., Hong, M. J., Kim, J., & Kim, S. Y. (2020) · Antioxidants · doi:10.3390/antiox9060531 · Cited by 24
“Detoxification enzymes, such as glyoxalase-I (GLO-I), are associated with the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2)/antioxidant response element (ARE) pathway [57,58].”
BackgroundAntioxidative Potentials of Incretin‐Based Medications: A Review of Molecular Mechanisms
Yaribeygi, H., Maleki, M., Sathyapalan, T., Jamialahmadi, T., & Sahebkar, A. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9959320 · Cited by 26
“In addition to their antihyperglycemic effects, recent evidence suggests that these medications could provide antioxidative effects [11, 12].”
BackgroundKopp, K. O., Li, Y., Glotfelty, E. J., Tweedie, D., & Greig, N. H. (2024) · Biomolecules · doi:10.3390/biom14070872 · Cited by 27
“The following supporting information can be downloaded at: https:// www.mdpi.com/article/10.3390/biom14070872/s1, The Supplementary Materials include the original Western blots.”
BackgroundInfluentialKaur, T., Sidana, P., Kaur, N., Choubey, V., & Kaasik, A. (2024) · Inflammopharmacology · doi:10.1007/s10787-024-01549-1 · Cited by 27
“It controls the expression of several genes involved in antioxidant, cyto-protective and detoxification processes (Oh and Jun 2018; Chakkittukandiyil et al. 2022).”
Mechanisms of the Regulation and Dysregulation of Glucagon Secretion
Onyango, A. N. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/3089139 · Cited by 23
“They promote cAMP formation, which, through Epac2, inhibits Src signaling and induces Nrf2 antioxidant response [25, 92].”
BackgroundBajpai, A., Bharathi, V., & Patel, B. K. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177187 · Cited by 23
Edaravone: A Novel Possible Drug for Cancer Treatment?
Duranti, E., Cordani, N., & Villa, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031633 · Cited by 26
“Nrf2 is known to play a role in protecting against oxidative stress through its activation of anti-inflammatory and antioxidative effects, regulating the expression of antioxidant and detoxification enzymes [120,121].”
BackgroundNabrdalik-Leśniak, D., Nabrdalik, K., Sedlaczek, K., Główczyński, P., Kwiendacz, H., Sawczyn, T., Hajzler, W., Drożdż, K., Hendel, M., Irlik, K., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/5593589 · Cited by 21
“Several drugs which already used to treat diabetes or under the investigation as potential therapeutic agents, such as metformin, glucagon-like peptide-1 receptor (GLP1R) agonists, and bardoxolone, were shown to upregulate Nrf2 [53, 54]; we did not find such data for SGLT2i except for limited data on an animal model w…”
BackgroundNrf2 Regulates Basal Glutathione Production in Astrocytes
He, J., & Hewett, S. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020687 · Cited by 25
“This activation enhances the transcription of antioxidant genes [26,28], including the key GSH synthetic enzymes (GCLc, GCLm, GS), as well as transporters that regulate substrate import (system x c − ) and GSH release (Mrp1) [29–31].”
Dewi, N. K. S. M., Ramona, Y., Saraswati, M. R., Wihandani, D. M., & Wirasuta, I. M. A. G. (2023) · Metabolites · doi:10.3390/metabo14010029 · Cited by 21
“14 of 23 Conversely, oxidative stress can be reduced by suppressing ROS through radical scavenging and chelating mechanisms, thus protecting pancreatic beta cells [51]. as MDA are used to assess oxidative stress, with increased levels indicating higher levels of lipid peroxidation.”
BackgroundWang, J., Hu, L., Chen, Y., Fu, T., Jiang, T., Jiang, A., & You, X. (2018) · Endocrine · doi:10.1007/s12020-018-1721-2 · Cited by 22
Singh, A., & Singh, L. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00672-8 · Cited by 23
Suryaningtyas, I. T., Ahn, C., & Je, J. (2021) · Marine Drugs · doi:10.3390/md19110609 · Cited by 20
“These risk factors can induce endothelial dysfunction (ED) through a variety of processes [4,5].”
BackgroundCardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
Lo, C. W. H., Fei, Y., & Cheung, B. M. Y. (2021) · Cardiac failure review · doi:10.15420/cfr.2020.19 · Cited by 23
Kuthati, Y., Rao, V. N., Busa, P., & Wong, C. (2021) · Antioxidants · doi:10.3390/antiox10091438 · Cited by 21
“GLP-1 is known to exert neuroprotection through suppression of neuroinflammatory, alleviation of oxidative stress, improving autophagy and apoptosis attenuation [45].”
BackgroundHomolak, J., Perhoč, A. B., Knezović, A., Barilar, J. O., & Šalković‐Petrišić, M. (2021) · Antioxidants · doi:10.3390/antiox10071118 · Cited by 19
Kanasaki, K., Kawakita, E., & Koya, D. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00476 · Cited by 20
“GLP-1 agonists have been shown to induce Nrf2 in β cells (Oh and Jun, 2017).”
BackgroundLim, J. C.-H., Jiang, L., Lust, N. G., & Donaldson, P. J. (2024) · Antioxidants · doi:10.3390/antiox13101193 · Cited by 23
Chen, A., Kang, Y., Liu, J., Wu, J., Feng, X., Wang, M., Zhang, Y., Wang, R., Lai, X., & Shao, L. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.049 · Cited by 21
Chanoine, J., Thompson, D. M., & Lehman, A. (2024) · Diabetes · doi:10.2337/db24-0515 · Cited by 28
Preventing Oxidative Stress in the Liver: An Opportunity for GLP-1 and/or PASK
Hurtado-Carneiro, V., Dongil, P., Pérez-García, A., Álvarez, E., & Sanz, C. (2021) · Antioxidants · doi:10.3390/antiox10122028 · Cited by 20
Semaglutide Enhances Cellular Regeneration in Skin and Retinal Cells In Vitro
Anastasiou, I. A., Tentolouris, A., Sarantis, P., Katsaouni, A., Rebelos, E., Mourouzis, I. S., Pantos, C. I., & Tentolouris, N. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091115 · Cited by 20
“Emerging research suggests that GLP-1 may exert antioxidative effects by reducing ROS levels, enhancing antioxidant enzyme activity, and modulating inflammatory responses [1,23,24].”
Exenatide reduces oxidative stress and cell death in testis in iron overload rat model
Yeşil, S., Süngü, N., Kılıçarslan, A., Kuşkonmaz, Ş. M., Kara, H., Küçük, A., Polat, F., Kavutçu, M., & Arslan, M. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6795 · Cited by 19
“Glucagon-like peptide-1 (GLP-1) has been demonstrated to affect the oxidative stress status in several in vitro (14,15), in vivo (16,17) and clinical (18,19) studies.”
BackgroundXue, S., Han, H., Rui, S., Yang, M., Huang, Y., Zhan, B., Geng, S., Liu, H., Chen, C., Yang, G., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6657658 · Cited by 17
Li, C., Miao, X., Lou, Y., Lu, Z., Adhikari, B. K., Wang, Y., Liu, Q., Sun, J., & Wang, Y. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13924 · Cited by 17
“Nuclear factor (erythroid‐derived 2)‐like 2 (Nrf2) is a transcription factor that controls redox balance through regulating expression of many antioxidant and anti‐inflammatory genes.(2) It has been reported that JNK inactivation can significantly activate Nrf2 and subsequently attenuate diabetes‐induced inflammation,…”
BackgroundRaut, S., & Cucullo, L. (2025) · Antioxidants · doi:10.3390/antiox14121490 · Cited by 21
“Simultaneously, GLP-1R agonism promotes antioxidant defense via upregulation of Nrf2, a transcription factor that enhances expression of superoxide dismutase (SOD) and other detoxifying enzymes, thus mitigating oxidative stress [98] (See Figure 4).”
The potential of glucagon-like peptide-1 receptor agonists in heart failure
Kreiner, F. F., Hovingh, G. K., & von Scholten, B. J. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.983961 · Cited by 17
“, 2021), hyperglycaemia (Mapanga and Essop, 2016), increased endothelial production of reactive oxygen species (ROS) (Ceriello et al., 2011; Li et al., 2017; Oh and Jun 2017; Lambadiari et al., 2018; Bray et al., 2021) and impaired vasodilation due to low nitrogen oxide bioavailability (Ceriello et al.”
BackgroundDuan, J., Zhao, Y., Pei, F., Deng, W., He, L., Rao, C., Zhai, Y., & Zhang, C. (2023) · Environmental Toxicology · doi:10.1002/tox.23764 · Cited by 15
“It binds ARE and regulates the expression of antioxidant oxidase genes and detoxification genes mediated by ARE.(17,19) For example, glutathione-S-transferase (GST), NAD(P)H quinone oxidoreductase (NQO1), HO-1, and so forth, maintain cell REDOX homeostasis.”
BackgroundLodato, M., Plaisance, V., Pawlowski, V., Kwapich, M., Barras, A., Buissart, E., Dalle, S., Szunerits, S., Vicogne, J., Boukherroub, R., et al. (2023) · Cells · doi:10.3390/cells12060940 · Cited by 17
Zheng, W., Li, L., & Li, H. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114817 · Cited by 16
Hardoňová, M., Šiarnik, P., Siváková, M., Sucha, B., Penesová, A., Rádiková, Ž., Havranová, A., Imrich, R., Vlček, M., Žitňanová, I., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311162 · Cited by 17
“The result is an increased expression of antioxidant enzymes and an increased activation of the nuclear factor erythroid-related factor 2 (Nrf2-ARE) pathway [38,39].”
BackgroundIncretin and glucagon receptor polypharmacology in chronic kidney disease
McFarlin, B. E., Duffin, K. L., & Konkar, A. A. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00374.2023 · Cited by 17
Pei, J., Cai, S., Song, S., Xu, Y., Feng, M., Luo, G., Wang, Y., Sun, F., Shi, H., & Xu, S. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.07.004 · Cited by 15
Metadata
- Authors
- Oh, Y., & Jun, H.-S.
- Affiliations
- Eulji University (KR)
- Gachon University (KR)
- Corresponding author
- Jun, Hee-Sook
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-12-22
- Volume
- 19
- Issue
- 1
- Pages
- 26
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5795977
- OpenAlex
- W2779001901
- Semantic Scholar
- 8fd8d98ecad3afa2039a39b8a6478a9494f9a746
- Cited by
- 217
- References
- 133
- Citations by year
- 2026: 24 · 2025: 50 · 2024: 41 · 2023: 19 · 2022: 21 · 2021: 31 · 2020: 12 · 2019: 9 · 2018: 9 · 2017: 1
- FWCI
- 0.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Research Foundation
- Korea Health Industry Development Institute (HI15C0987)
- National Research Foundation of Korea (NRF-2015R1D1A1A01058888)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
- Keywords
- glucagon-like peptide-1, Nrf2 signaling, Keap1, oxidative stress, antioxidant defense, incretins, GLP-1 receptor agonists, free radicals, cellular stress response, diabetes mellitus
- MeSH terms
- Animals, Diabetes Mellitus, Humans, Nervous System Diseases, Signal Transduction, Reactive Oxygen Species, Oxidative Stress, NF-E2-Related Factor 2, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.